Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1868-7083
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia ; volume:11 ; number:1 ; day:22 ; month:7 ; year:2019 ; pages:1-12 ; date:12.2019
Clinical epigenetics ; 11, Heft 1 (22.7.2019), 1-12, 12.2019

Urheber
Chung, Woonbok
Kelly, Andrew D.
Kropf, Patricia
Fung, Henry
Jelinek, Jaroslav
Su, Xiang Yao
Roboz, Gail J.
Kantarjian, Hagop M.
Azab, Mohammad
Issa, Jean-Pierre J.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13148-019-0704-3
URN
urn:nbn:de:101:1-2019122221250322557853
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:59 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Chung, Woonbok
  • Kelly, Andrew D.
  • Kropf, Patricia
  • Fung, Henry
  • Jelinek, Jaroslav
  • Su, Xiang Yao
  • Roboz, Gail J.
  • Kantarjian, Hagop M.
  • Azab, Mohammad
  • Issa, Jean-Pierre J.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations

Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Verbundene Objekte